Re. Warnick et al., A PHASE-II STUDY OF INTRAVENOUS CARBOPLATIN FOR THE TREATMENT OF RECURRENT GLIOMAS, Journal of neuro-oncology, 19(1), 1994, pp. 69-74
Thirty-two patients with recurrent glioma who had previously received
radiation therapy and chemotherapy with nitrosoureas were treated with
intravenous carboplatin every 3 weeks, starting at a dose of 350 mg/m
(2), with a dose escalation of 25 mg/m(2) every 6 weeks until a level
4 hematologic toxicity was reached. Of the 28 patients who could be ev
aluated for a response, 50% demonstrated a response or had stabilizati
on of their disease after two infusions of carboplatin. Their median t
ime to tumor progression and median duration of survival were 19 weeks
and 38 weeks. Thrombocytopenia was the major toxicity and was severe
in one-third of the patients. No neurologic or renal toxicities were n
oted. Carboplatin has demonstrated activity against recurrent gliomas
in patients who have already had extensive chemotherapy Increasing the
dose of carboplatin may improve the rate of response and the duration
of progression-free survival in patients with recurrent glioma.